Dermatitis

Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Retrieved on: 
Wednesday, February 14, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Therapy, Atopic dermatitis, Psoriasis, Caregiver, Food, Shanda, Sleep, Patient, Dermatitis, Itch, Skin, Pharmaceutical industry

VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of AD.

Key Points: 
  • VTAMA cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of AD.
  • VTAMA cream, 1% data indicated no new safety or tolerability signals of concern in this population including children 2 years of age and older.
  • On May 24, 2022, Dermavant announced the FDA approved VTAMA® (tapinarof) cream, 1% for the treatment of plaque psoriasis in adults.
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

U.S. Dermatology Partners Announces the Opening of Greenville, Texas Office

Retrieved on: 
Wednesday, February 14, 2024
Skin cancer, Acne, Psoriasis, Certification, Dermatology, World War II, Life, History, Medal, Patient, Audie, Dermatitis, Partner, Hospital

GREENVILLE, Texas, Feb. 14, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Greenville, Texas. The Greenville location is the latest addition to the U.S. Dermatology Partners' Outreach Program which is dedicated to serving the healthcare needs of rural and underserved communities. The organization aims to increase access to professional dermatologic care in rural areas by introducing over 30 new locations across eight states. These new offices, including the Greenville location, will offer patients easier and more convenient access to much-needed care. Beginning February 14th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Hunt County. The new facility will provide care for various dermatologic conditions, including acne, psoriasis, eczema, and skin cancer.

Key Points: 
  • GREENVILLE, Texas, Feb. 14, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Greenville, Texas.
  • The Greenville location is the latest addition to the U.S. Dermatology Partners' Outreach Program which is dedicated to serving the healthcare needs of rural and underserved communities.
  • Beginning February 14th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Hunt County.
  • Today's announcement builds on U.S. Dermatology Partners' recent openings of offices in Alva, Oklahoma, Kaufman, Texas, and Peoria, Arizona.

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Retrieved on: 
Monday, February 12, 2024
Atopic dermatitis, Immunodeficiency, Psoriasis, Infection, SQL, ITK, Scleroderma, Preprint, Asthma, T helper cell, Pulmonary fibrosis, T helper 17 cell, Venn, Lymphocyte, Cytokine, Rheumatoid arthritis, Immunosuppression, Dermatitis, Publication, Lymphoma, Research, Immunomodulation, Vaccine

BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.

Key Points: 
  • BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.
  • These preclinical product candidates exhibit specific biologic properties that are anticipated to enable more precise inhibition of Th1, Th2 and/or Th17 cell function.
  • Atopic dermatitis (also called eczema) and asthma are thought to be mediated primarily by Th2 lymphocytes.
  • The soquelitinib preclinical data and information on the Company’s next-generation ITK inhibitor candidates was presented by Rahul Pawar, Ph.D., Senior Scientist at Corvus, in poster session #2 (poster #2008) at the Keystone Symposia.

U.S. Dermatology Partners Announces the Opening of Alva, Oklahoma Office

Retrieved on: 
Monday, February 12, 2024
Skin cancer, Psoriasis, Acne, Dermatology, Land Run of 1893, Public key certificate, OK, Natural history, Alva, Oklahoma, Northwestern Oklahoma State University, Patient, Dermatitis, Partner, Hospital

ALVA, Okla., Feb. 12, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Alva, Oklahoma. This new location is the latest addition to the organization's Outreach Program, which is committed to serving rural and underserved communities. To improve access to professional dermatologic care in rural areas, U.S. Dermatology Partners is launching more than 30 new locations across eight states. These new offices, including the Alva location, will provide patients with more convenient access to the care they need and deserve. Beginning February 12th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Woods County. The new facility will provide care for various dermatologic conditions, including acne, psoriasis, eczema, and skin cancer.

Key Points: 
  • U.S. Dermatology Partners expands access to dermatology care to patients in Woods County with the opening of the organization's newest office location.
  • ALVA, Okla., Feb. 12, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Alva, Oklahoma.
  • To improve access to professional dermatologic care in rural areas, U.S. Dermatology Partners is launching more than 30 new locations across eight states.
  • Beginning February 12th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Woods County.

Herbal medicinal product: Lecithinum ex soyaArray, D: Draft under discussion

Retrieved on: 
Saturday, February 10, 2024
Mouth, Soybean, Plant, Pea, Pollen, Allergy, Inflammation, Skin, Dermatitis, Agency, Diarrhea, Fatigue, Date, Monograph, Itch, Herbal medicine, Patient, Rash, Weakness, Exanthem, Medicine, Swelling, Angioedema, Committee, Medicinal plants

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of soya-bean lecithin.
  • Herbal medicines containing soya-bean lecithin are usually available in solid or liquid forms to be taken by mouth.
  • Soya-bean lecithin may also be found in combination with other herbal substances in some herbal medicines.
  • Key facts
    - Latin name
    - Lecithinum ex soya
    - English common name
    - Soya-bean lecithin
    - Botanical name
    Glycine max (L.) Merr.

Boudreaux's® Butt Barrier® Ointment Awarded 2024 Product of the Year

Retrieved on: 
Friday, February 9, 2024
Trust, Pediatrics, Skin, Associate, Irritation, Safety, Topical medication, Kantar, Parent, Prestige Consumer Healthcare, Butt, Dermatitis, Petroleum jelly

TARRYTOWN, N.Y., Feb. 9, 2024 /PRNewswire/ -- Boudreaux's Butt Paste's Butt Barrier® Ointment has been honored as a recipient of the prestigious 2024 Product of the Year USA Award, recognized as the top product in the baby care category based on a survey of 40,000 people by Kantar. The Product of the Year USA Award is one of the most respected honors in the consumer goods industry, celebrating excellence in product innovation and quality. Boudreaux's Butt Barrier® Ointment stood out among a competitive field of products, showcasing its effectiveness in preventing diaper rash while maintaining the highest standards of safety and reliability.

Key Points: 
  • TARRYTOWN, N.Y., Feb. 9, 2024 /PRNewswire/ -- Boudreaux's Butt Paste's Butt Barrier® Ointment has been honored as a recipient of the prestigious 2024 Product of the Year USA Award, recognized as the top product in the baby care category based on a survey of 40,000 people by Kantar.
  • Boudreaux's Butt Barrier® Ointment stood out among a competitive field of products, showcasing its effectiveness in preventing diaper rash while maintaining the highest standards of safety and reliability.
  • Developed with the utmost care and expertise by Boudreaux's Butt Paste's team of experts, Boudreaux's Butt Barrier® Ointment offers a unique blend of ingredients designed to create a protective barrier against wetness and irritation.
  • The Butt Barrier® Ointment is clinically tested, hypoallergenic, fragrance free and has been accepted by the National Eczema Association.

U.S. Dermatology Partners Announces the Opening of Kaufman, Texas Office

Retrieved on: 
Tuesday, February 6, 2024
Skin cancer, Dermatitis, Patient, Psoriasis, Veterans Memorial Park, Dermatology, Partner, Public key certificate, Acne, Hospital

KAUFMAN, Texas, Feb. 6, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Kaufman, Texas. This new location is the latest addition to the organization's Outreach Program, which is committed to serving rural and underserved communities. To improve access to professional dermatologic care in rural areas, U.S. Dermatology Partners is launching more than 30 new locations across eight states. These new offices, including the Kaufman location, will provide patients with more convenient access to the care they need and deserve. Beginning February 6th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Kaufman County. The new facility will provide comprehensive care for various dermatologic conditions, including acne, psoriasis, eczema, and skin cancer.

Key Points: 
  • U.S. Dermatology Partners expands access to dermatology care to patients in Kaufman County with the opening of the organization's newest office location.
  • KAUFMAN, Texas, Feb. 6, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the opening of its newest office location in Kaufman, Texas.
  • To improve access to professional dermatologic care in rural areas, U.S. Dermatology Partners is launching more than 30 new locations across eight states.
  • Beginning February 6th, the office will extend convenient access to dermatology and skin cancer treatments for patients in Kaufman County.

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

Retrieved on: 
Thursday, February 1, 2024
Hypothermia, Sodium nitrite, Fatigue, Ototoxicity, Cisplatin, Patient, FENC, STS, FDA, Restless, Kidney, TSX, Argyreia nervosa, Communication, Food, Methemoglobinemia, Risk, Dermatitis, Headache, Potassium chloride, Pharmaceutical industry

PEDMARK is the first and only FDA approved therapy indicated to reduce the risk of ototoxicity (e.g., permanent hearing loss) associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Key Points: 
  • PEDMARK is the first and only FDA approved therapy indicated to reduce the risk of ototoxicity (e.g., permanent hearing loss) associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.
  • The FDA reminded health care providers that as stated in PEDMARK’s prescribing information , PEDMARK is not substitutable with other sodium thiosulfate products.
  • Sodium nitrite is co-packaged with sodium thiosulfate as a separate vial in some products; it is not present in PEDMARK.
  • The FDA encourages those with any questions to contact [email protected].

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

Retrieved on: 
Monday, January 29, 2024
IGA, Patient, JAAD, FAAD, MD, Manuscript, Face, Success, Dermatitis, Scalp, Quality of life, BSA, MBA, Body surface area, Food, Journal, Disease, Safety, Study, FDA, Doctor of Philosophy, Week, Pharmaceutical industry

“Despite being very common, seborrheic dermatitis has traditionally been a disease with limited treatment options.

Key Points: 
  • “Despite being very common, seborrheic dermatitis has traditionally been a disease with limited treatment options.
  • These results highlight the effectiveness and safety of roflumilast foam, a steroid-free treatment and the first novel mechanism of action approved for seb derm in two decades.
  • Roflumilast foam also demonstrated statistically significant improvement over vehicle on all secondary endpoints, including itch, scaling, and erythema (redness).
  • The most common adverse reactions (≥1%) reported, per the prescribing information, include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

Retrieved on: 
Monday, January 22, 2024
IGA, PBM, Patient, MD, PAP, Dermatitis, Quality of life, Pharmacy, Skin, Food, FDA, Webcast, EST

ZORYVE is a once-daily steroid-free foam and is the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.

Key Points: 
  • ZORYVE is a once-daily steroid-free foam and is the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.
  • “Despite being a very common condition with significant negative impact on quality of life, seborrheic dermatitis has largely been overlooked by the pharmaceutical industry,” said Todd Edwards , chief commercial officer at Arcutis.
  • ZORYVE foam possesses several unique qualities that address unmet needs of seborrheic dermatitis patients.
  • An archived version of the webcast will be available on the Arcutis website after the call.